Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Cardiology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Superficial thrombophlebitis

Cardiology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

New whole-limb swelling, chest pain, breathlessness, haemoptysis or syncope requires urgent DVT/PE assessment. Rapid extension to the groin/popliteal fossa or SVT within 3 cm of a deep-vein junction needs same-day thrombosis review.

Overview

Distinguish low-risk superficial vein thrombosis from disease near the deep system, exclude concomitant DVT and use evidence-based anticoagulation when extension risk is material.

SVT commonly affects a varicose great saphenous tributary, but the clinically important questions are whether deep thrombosis is already present and how close the clot lies to a deep-vein junction.

Anatomy, length and patient risk—not redness alone—determine anticoagulation. Fondaparinux has a licensed UK regimen for isolated, spontaneous lower-limb SVT at least 5 cm long after DVT and SVT within 3 cm of the saphenofemoral junction have been excluded.

Upper-limb cannula-related phlebitis is assessed differently: remove an unnecessary cannula, look for infection or extension and investigate central/upper-extremity DVT when swelling is extensive or a central device is involved.

Key points

  • Superficial vein thrombosis (SVT) produces a tender, erythematous, palpable cord along a superficial vein; it is not always benign.
  • Duplex ultrasound should define thrombus length, distance from the saphenofemoral/saphenopopliteal junction and any concomitant DVT when disease is extensive, proximal or clinically uncertain.
  • SVT at least 5 cm long and at least 3 cm from a deep-vein junction is treated with fondaparinux 2.5 mg subcutaneously once daily for 45 days when suitable.
  • SVT within 3 cm of a deep-vein junction is managed as high-risk extension with therapeutic anticoagulation, usually for 3 months after specialist assessment.
  • A short SVT below 5 cm and more than 3 cm from the deep system, without high-risk features, can usually receive mobilisation, local measures and analgesia/NSAID rather than anticoagulation.
  • Cancer, previous VTE, thrombophilia, pregnancy, recent surgery, non-varicose-vein SVT and rapid progression lower the threshold for imaging and specialist treatment.
  • Do not prescribe antibiotics unless there is separate cellulitis, suppuration or another bacterial infection; erythema over thrombus is inflammatory.
  • After the acute episode, assess symptomatic varicose veins/venous reflux because definitive venous treatment may reduce recurrence.

Aetiology

01

Varicose veins and venous reflux

Dilated, poorly emptying superficial veins create local stasis and wall inflammation, making a varicose great-saphenous tributary a common site for superficial thrombosis.

02

Transient venous thromboembolism risks

Recent surgery, immobility, pregnancy, the postpartum period and oestrogen exposure increase stasis or coagulability and may produce more extensive superficial disease.

03

Persistent prothrombotic states

Active cancer, previous venous thromboembolism and thrombophilia increase extension and recurrence risk, especially when thrombosis arises in a previously normal non-varicose vein.

04

Cannula-related or septic injury

A peripheral cannula can injure an upper-limb superficial vein. Purulence, fever or systemic toxicity suggests superimposed infection rather than uncomplicated sterile inflammation.

Pathophysiology

  1. 1
    Thrombogenic conditions develop

    Local venous stasis, endothelial injury or systemic hypercoagulability shifts haemostasis towards fibrin-rich thrombus within a superficial vein of the affected limb.

  2. 2
    Local inflammation follows

    Thrombus and vessel-wall inflammation produce pain, warmth and linear erythema along the affected vein; cellulitis more often produces diffuse tissue inflammation.

  3. 3
    A palpable cord forms

    The thrombosed, inflamed vein becomes firm and tender, creating a linear cord that tracks the anatomical course of a superficial vessel.

  4. 4
    Propagation may reach deep veins

    Thrombus can extend proximally through a saphenous junction or perforating vein into the deep system, where it behaves as deep-vein thrombosis and may embolise.

Clinical features and red flags

Typical SVT

Localised pain, warmth, erythema and a firm tender cord tracking a superficial vein, often within visible varicosities.

Proximal extensionRed flag

Cord or inflammation approaching the groin or popliteal fossa, rapid proximal spread or extensive length raises deep-system extension risk.

Concomitant DVTRed flag

Whole-leg swelling, deep calf tenderness, pitting oedema or risk factors out of proportion to the superficial segment require the NICE DVT pathway.

Pulmonary embolismRed flag

New dyspnoea, pleuritic pain, haemoptysis, tachycardia, syncope or hypoxia requires emergency PE assessment.

Septic thrombophlebitis

Purulence, cannula-site infection, fever, rigors or systemic toxicity suggests infection rather than uncomplicated sterile SVT and requires cultures/source control.

High-risk context

Active cancer, prior VTE, pregnancy/postpartum, thrombophilia, recent surgery or SVT in a previously normal non-varicose vein warrants a lower threshold for comprehensive assessment.

Investigations

  1. 01
    Whole-leg duplex ultrasoundFirst step
    Why
    Confirm SVT length and location, measure distance to deep junctions and exclude DVT.
    Interpretation and limitations
    Document the proximal end in centimetres from the saphenofemoral/saphenopopliteal junction; within 3 cm is high risk and not the licensed isolated-SVT fondaparinux population.
  2. 02
    Two-level DVT Wells pathway when DVT suspected
    Why
    Avoid missing a separate deep clot.
    Interpretation and limitations
    Apply NICE Wells/D-dimer/proximal-ultrasound timing rather than using an SVT diagnosis as reassurance.
  3. 03
    FBC, renal and liver function, PT/APTT
    Why
    Establish safety before anticoagulation and identify platelet, renal or hepatic modifiers.
    Interpretation and limitations
    Renal function is particularly important for fondaparinux; active bleeding or major thrombocytopenia changes treatment.
  4. 04
    Clinical infection assessment with cultures if purulent/systemically unwell
    Why
    Identify septic thrombophlebitis or cellulitis.
    Interpretation and limitations
    Routine blood tests or antibiotics are unnecessary for uncomplicated afebrile SVT; obtain cultures before antibiotics when feasible in sepsis.

Differential diagnosis

01

Deep-vein thrombosis

Whole-limb swelling, deep calf tenderness and pitting oedema out of proportion to a superficial cord raise concern for concomitant or alternative deep thrombosis.

02

Cellulitis

Diffuse spreading erythema, skin tenderness, fever and no palpable venous cord favour cellulitis; sterile superficial thrombosis can still produce striking local redness, and the conditions can coexist.

03

Lymphangitis

Fine red streaking towards regional lymph nodes, a skin portal and tender lymphadenopathy suggest lymphatic infection rather than thrombosis confined to a superficial vein.

04

Ruptured Baker's cyst or muscle injury

Posterior knee pathology, bruising or pain linked to movement may mimic calf thrombosis; duplex imaging clarifies venous anatomy when clinical distinction remains uncertain.

05

Superficial abscess or septic thrombophlebitis

Fluctuance, purulent drainage, an infected cannula, fever or rigors indicate a focal or intravascular infection requiring cultures and source control.

Management

01low riskShort distal SVTFirst stepSVT <5 cm long, >3 cm from a deep junction, no DVT and no major extension-risk feature.+
  1. 1First: encourage mobilisation as tolerated, limb elevation when resting and warm/cool compresses according to comfort.
  2. 2Next: offer topical/oral NSAID or paracetamol if safe; avoid antibiotics without infection.
  3. 3Next: give explicit return advice for proximal spread, whole-leg swelling or PE symptoms.
  4. 4EscalationEscalation: arrange duplex/reassessment if symptoms extend or fail to improve over about a week.
02intermediate riskSVT at least 5 cm and away from junctionAcute symptomatic isolated lower-limb SVT at least 5 cm long and at least 3 cm from the deep venous junction.+
  1. 1First: confirm anatomy and exclude concomitant DVT

Complications

01

Extension into the deep venous system

A clot approaching a saphenofemoral or saphenopopliteal junction can propagate into deep veins, changing both embolic risk and the required treatment intensity.

02

Pulmonary embolism

If superficial thrombus propagates into the deep circulation, embolisation to pulmonary arteries can cause acute dyspnoea, pleuritic pain, haemoptysis, syncope or haemodynamic collapse.

03

Recurrent superficial thrombosis

Untreated venous reflux or a persistent systemic driver can predispose to repeated episodes, chronic local discomfort and further opportunities for proximal propagation.

04

Septic thrombophlebitis

Bacterial infection of thrombus, particularly around an intravascular device, may seed the bloodstream and cause persistent bacteraemia, sepsis or metastatic infection.

Monitoring and follow-up

  • Mark/document the proximal extent and review promptly if redness, cord or pain advances.
  • During fondaparinux, monitor bleeding, haemoglobin/platelets when clinically indicated and renal function if unstable or impaired.
  • Ask at every review about whole-leg swelling and PE symptoms.
  • Confirm completion of 45 days or, for junctional/deep extension, the documented therapeutic-duration plan.
  • After recovery, review recurrent SVT and symptomatic varicose veins for duplex-guided venous treatment.

Special situations

Centimetres determine the pathway

The ultrasound report should state both clot length and exact distance from the deep junction.

Fondaparinux dose is prophylactic-intensity

The 2.5 mg dose is effective for eligible isolated SVT but is not adequate treatment for DVT or junctional extension managed as VTE.

Red does not mean infected

Sterile venous inflammation commonly causes erythema; antibiotics need separate clinical evidence of infection.

Non-varicose SVT deserves more thought

SVT in a normal vein is more strongly associated with systemic provoking factors than a short clot in established varicosities.

Upper-limb SVT is not automatically low risk

Central devices, diffuse arm swelling or symptoms beyond a peripheral cannula site require upper-extremity DVT/central obstruction assessment.

Common pitfalls

  1. 01

    Calling all superficial thrombosis benign without measuring proximity to the deep system.

  2. 02

    Using D-dimer alone to diagnose or exclude an anatomically high-risk SVT.

  3. 03

    Giving fondaparinux 2.5 mg for a clot already within 3 cm of the junction as though it were low risk.

  4. 04

    Prescribing antibiotics for uncomplicated inflammatory erythema.

  5. 05

    Combining oral NSAIDs with anticoagulation without considering GI and bleeding risk.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
CardiologyOriginal SBA

Eligible SVT anticoagulation

Duplex confirms a symptomatic great saphenous SVT 8 cm long, ending 5 cm from the saphenofemoral junction, with no DVT. Renal function and bleeding risk are acceptable. What is the best treatment?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Cardiology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • ESVS 2021 Clinical Practice Guidelines on Venous ThrombosisSVT anatomical risk bands and anticoagulation duration.
  • eMC: Arixtra 2.5 mg SmPCLicensed SVT population, 2.5 mg dose, duration and renal modifiers.
  • NHS: PhlebitisRecognition and urgent symptom advice.
  • NICE NG158: Venous thromboembolic diseasesDVT/PE pathway when deep extension is suspected or confirmed.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • 05
    Targeted malignancy/thrombophilia review
    Why
    Identify an underlying driver in recurrent, migratory or unprovoked non-varicose SVT.
    Interpretation and limitations
    Use history, examination and age-appropriate pathways; do not order indiscriminate tumour markers or thrombophilia panels during acute anticoagulation.
    • by duplex.
  • 2Next: give fondaparinux 2.5 mg subcutaneously once daily for 45 days when renal function and bleeding risk allow.
  • 3Next: continue mobilisation and symptom control; review adherence, bleeding and extension.
  • 4EscalationEscalation: treat any propagation to within 3 cm or new DVT/PE through the therapeutic VTE pathway.
    • 03high riskSVT close to deep systemProximal thrombus within 3 cm of the saphenofemoral/saphenopopliteal junction or progression into a deep vein.+
    1. 1First: same-day thrombosis/vascular assessment and full duplex mapping.
    2. 2Next: use therapeutic-dose anticoagulation rather than prophylactic-dose fondaparinux, generally for 3 months, with agent selected as for VTE.
    3. 3Next: assess cancer, pregnancy, renal function, APS and bleeding modifiers.
    4. 4EscalationEscalation: emergency PE pathway for respiratory/chest symptoms or vascular review for severe venous outflow compromise.
    04recurrentAfter the acute episodeSVT associated with varicose veins, recurrence or persistent symptomatic reflux.+
    1. 1First: reassess after inflammation settles and confirm whether varicose truncal reflux is present.
    2. 2Next: refer to a vascular service for duplex and interventional options when symptomatic varicose veins or recurrent SVT meets NICE criteria.
    3. 3Next: address weight, mobility, smoking, oestrogen and other individual VTE risks.
    4. 4EscalationEscalation: specialist evaluation for recurrent migratory or non-varicose SVT without an explanation.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    Prevents extension/DVT/PE in isolated spontaneous lower-limb SVT at least 5 cm long and at least 3 cm from the saphenofemoral junction.

    Fondaparinux

    2.5 mg subcutaneously once daily for 45 days (licensed course is a minimum of 30 and maximum of 45 days in the eligible high-risk population).

    Do not use this low-dose regimen for SVT within 3 cm of the junction. Contraindicated if CrCl <20 mL/min; reduce to 1.5 mg daily at CrCl 20–50 mL/min, noting that this reduced dose has not been studied for efficacy/safety. For the SVT indication the SmPC does not recommend fondaparinux below 50 kg, and active cancer/recent VTE were not studied.

    Short-term pain and inflammation relief in low-risk SVT or alongside anticoagulation only when bleeding risk is acceptable.

    Ibuprofen

    400 mg orally three times daily with/after food for up to 5–7 days when needed.

    Avoid or minimise with anticoagulation, peptic ulcer, CKD, heart failure, uncontrolled hypertension or pregnancy; topical NSAID may have less systemic exposure.

    Analgesic when NSAIDs are unsuitable.

    Paracetamol

    500 mg–1 g orally every 4–6 hours as needed, maximum 4 g in 24 hours (lower maximum in low body weight, frailty or liver risk).

    Check combination products and hepatic/alcohol risk.